BVF INC/IL - Q2 2016 holdings

$469 Million is the total value of BVF INC/IL's 34 reported holdings in Q2 2016. The portfolio turnover from Q1 2016 to Q2 2016 was - .

 Value Shares↓ Weighting
IONS NewIONIS PHARMACEUTICALS INC$19,797,000850,000
+100.0%
4.22%
GLYC NewGLYCOMIMETICS INC$17,793,0002,447,415
+100.0%
3.79%
CASC NewCASCADIAN THERAPEUTICS INC$17,730,00018,799,368
+100.0%
3.78%
PRTK NewPARATEK PHARMACEUTICALS INC$7,998,000575,000
+100.0%
1.70%
INFI NewINFINITY PHARMACEUTICALS INC$6,896,0005,184,600
+100.0%
1.47%
ADRO NewADURO BIOTECH INC$5,809,000513,603
+100.0%
1.24%
MGNX NewMACROGENICS INC$5,398,000200,000
+100.0%
1.15%
OREX NewOREXIGEN THERAPEUTICS INC$2,258,0005,252,100
+100.0%
0.48%
PIRS NewPIERIS PHARMACEUTICALS INC$389,000241,352
+100.0%
0.08%
AVIR NewAVIRAGEN THERAPEUTICS INC$292,000208,353
+100.0%
0.06%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2016-08-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
XENON PHARMACEUTICALS INC37Q4 20234.7%
PIERIS PHARMACEUTICALS INC32Q1 20242.8%
XOMA CORP DEL31Q2 20247.3%
CYTOKINETICS INC29Q4 202011.8%
INFINITY PHARMACEUTICALS INC29Q2 20234.3%
CYTOMX THERAPEUTICS INC29Q2 20245.3%
KURA ONCOLOGY INC28Q2 20245.1%
CORVUS PHARMACEUTICALS INC28Q1 20242.3%
ARQULE INC27Q4 20194.8%
GLYCOMIMETICS INC27Q2 20245.7%

View BVF INC/IL's complete holdings history.

Latest filings
TypeFiled
N-PX2024-09-03
42024-08-22
13F-HR2024-08-14
32024-08-01
42024-06-28
42024-06-18
42024-06-10
13F-HR2024-05-15
42024-05-13
13F-HR2024-02-14

View BVF INC/IL's complete filings history.

Compare quarters

Export BVF INC/IL's holdings